The cost effectiveness of nalmefene for reduction of alcohol consumption in alcohol-dependent patients with high or very high drinking-risk levels from a UK societal perspective

Brodtkorb TH, Bell M, Irving AH, Laramée P. CNS drugs 2016; 30(2):163-177

ARTICLE IDENTIFIERS

DOI: 10.1007/s40263-016-0310-2

PMID: 26879458 PMCID: not available

JOURNAL IDENTIFIERS

LCCN: not available pISSN: 1172-7047 eISSN: 1179-1934 OCLC ID: not available CONS ID: not available

US National Library of Medicine ID: not available

This article was identified from a query of the SafetyLit database.